Navigation Links
Depth of MedImmune's Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society

GAITHERSBURG, Md., May 15 /PRNewswire/ -- MedImmune today announced that researchers will present eight abstracts from its respiratory disease program at the Annual Meeting of the American Thoracic Society, from May 18 to 20, 2008 in Toronto, Canada. Presentations are designed to showcase MedImmune's biologics capabilities.

"MedImmune is committed to finding innovative solutions that may one day help patients struggling with respiratory diseases," said Tony Coyle, vice president, head, autoimmunity inflammation and respiratory disease research. "We are pleased to present a plethora of promising data that could potentially address diseases such as asthma and chronic obstructive pulmonary disease."

MedImmune research scheduled to be presented includes:

-- Regulation of Lung Inflammation in Animal Models (Poster Session:

IL-33, the Ligand for T1/ST2, Induces Airway Hyperresponsiveness Via a

Mast Cell but Not T Cell Dependent Mechanism, publication page A63)

- Sunday, May 18 from 8:15 a.m.- 4:15 p.m., Metro Toronto Convention

Centre, Area E.

-- Viral Infection and Wheezing (Poster Session: Evidence for T-Lymphocyte

Independent Antibody Responses in Primary RSV Infection, publication

page A190)-Sunday, May 18 from 8:15 a.m. - 4:15 p.m., Metro Toronto

Convention Centre, Area A.

-- Chitins: Flying High (Symposium: Hyperresponsiveness and Inflammation

in a Murine Model of Asthma, publication page A501)- Monday, May 19 at

2:45 p.m., Ontario, Fairmont Royal York Hotel.

-- New Insights and Developing Controversies in Clinical Asthma (Poster

Session: Safety Profile, Pharmacokinetics and Biologic Activity of a

Single IV Dose of the Anti IL-5 Receptor Alpha Antibody MEDI-563 in

Patients with Mild Asthma, publication page A569)-Tuesday, May 20 from

8:15 a.m.- 11:00 a.m., Metro Toronto Convention Centre, Room 205A.

-- Eosinophils, Mast Cells and Neutrophils as Modulators of Immunity and


-- Poster Session: In Vitro Characterization of MEDI-563, a Humanized

Anti-IL-5Ralpha Monoclonal Antibody in Phase1 Clinical Trial,

publication page A602

-- Poster Session: MEDI-563, a Humanized Anti-Human IL-5R alpha Antibody

Binds to Lung Tissue Eosinophils in Asthmatic Patients, publication

page A602

-- Poster Session: A Monoclonal Anti-IL-5 Receptor (IL-5R) alpha

Antibody with Enhanced ADCC Selectively and Efficaciously Depletes

Tissue Eosinophils in IL-5 Transgenic Mice, publication page A603

The preceding presentations will occur on Tuesday, May 20 from 8:15 a.m. - 4:15 p.m., Metro Toronto Convention Centre, Area B.

-- Monocytes and Macrophages in Inflammation, Immunity and Injury (Poster

Session: Role for Alveolar Macrophages in Limiting Primary RSV

Immunopathology, publication page A623) - Tuesday, May 20 from 8:15

a.m. - 4:15 p.m., Metro Toronto Convention Centre, Area B.

About MedImmune

MedImmune is wholly owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN) and is the worldwide biologics business for the AstraZeneca Group. The company has approximately 3,000 employees worldwide and is headquartered in Gaithersburg, Maryland. MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience. For more information, visit MedImmune's website at

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Respiratory/Pulmonary Indexes
2. Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions
3. PARI Respiratorys LC PLUS & PRONEB Ultra Deliver Dey, L.P.s New COPD Therapy; Perforomist Launched Yesterday
4. Adams Respiratory Therapeutics and Lipocine Enter into License and Collaboration Agreement
5. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008
6. Retired Supreme Court Justice Sandra Day OConnor and Former House Speaker Newt Gingrich Address Senate Special Committee on Aging, Calling for Urgent Action Against Alzheimers Disease
7. ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics
8. Vermillions Roundtable Teleconference Highlights Peripheral Artery Disease Diagnostic Program; Features Commentary from Vascular Medicine Expert
9. Novel Approach to Treat Alzheimers and Other Diseases Offered by Targeting Cell Membrane RAFTS
10. Liver Diseases: A Huge European Health Burden, But Some Trends are Positive
11. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
Post Your Comments:
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015  Neurocrine ... Kevin Gorman , President and CEO of Neurocrine ... Jaffray Healthcare Conference in New York ... encouraged to visit the website approximately 5 minutes prior ... software.  A replay of the presentation will be available ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... featured on AngelList early in their initial angel funding process. Now, they are ... individuals looking to make early stage investments in the microbiome space. In ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... November 24, 2015 --> ... research report "Oligonucleotide Synthesis Market by Product & Services ... Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, ... MarketsandMarkets, the market is expected to reach USD 1,918.6 ... at a CAGR of 10.1% during the forecast period. ...
Breaking Biology Technology:
(Date:11/17/2015)... November 17, 2015 Paris ... 2015.  --> Paris , qui ... DERMALOG, le leader de l,innovation biométrique, a inventé ... passeports et empreintes sur la même surface de balayage. ... et l,autre pour les empreintes digitales. Désormais, un seul ...
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
Breaking Biology News(10 mins):